Daraxonrasib Data Rewrites the Playbook - Upgrade to Long
Revolution Medicines delivered a landmark Phase 3 RASolute 302 result for daraxonrasib that doubled median overall survival in previously treated metastatic pancreatic cancer and produced a 60% reduction in risk of death. That clinical leap turns a clinical-stage oncology name into a commercial opportunity. We upgrade our stance to a tactical long …